← All trials
NCT03862170
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2015
- Primary completion
- Feb 29, 2020
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 255
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CSSS Champlain - Charles-Lemoyne HospitalLead sponsor
- CSSS Champlain - Charles-Lemoyne HospitalOverall official - principal investigator
- CSSS Champlain - Charles-Lemoyne HospitalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.